NCT05180019 (AUTOECOSMD) is a clinical trial of SMD ( Self Monitoring Device) in Self-Evaluation, sponsored by IVI Bilbao.

Who is sponsoring NCT05180019?

NCT05180019 is sponsored by IVI Bilbao.

What drugs are being tested in NCT05180019?

Interventions in NCT05180019: SMD ( Self Monitoring Device).

What condition does NCT05180019 study?

NCT05180019 studies Self-Evaluation.

Is NCT05180019 still recruiting?

NCT05180019 is currently completed. Last updated 2 May 2025.

Last reviewed 2025-05-02 · How we verify

NCT05180019: AUTOECOSMD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Self Monitoring Device Fortrasvaginal Ultrasound in Reproduction

Completed Last updated 2 May 2025

What this trial tests

trial testing SMD ( Self Monitoring Device) in Self-Evaluation in 101 participants. Completed in 8 May 2023.

Timeline

9 February 2022

Primary endpoint
8 May 2023

8 May 2023

Quick facts

Lead sponsor	IVI Bilbao
Status	Completed
Study type	OBSERVATIONAL
Enrollment	101
Start date	9 February 2022
Primary completion	8 May 2023
Estimated completion	8 May 2023
Sites	1 location across Spain

Drugs / interventions tested

SMD ( Self Monitoring Device)

Conditions studied

Self-Evaluation — all drugs for Self-Evaluation →

Sponsor

IVI Bilbao — full company profile →

Who can join

Adults 18 to 49, female only, with Self-Evaluation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Serial ultrasound (US) examinations are performed to assess the number and size of follicles during controlled ovarian stimulation (COS). Ovarian folliculometry during COS is the most frequent ultrasound procedure daily performed, an also a highly time consuming and reiterative process. However, it has been shown that manual measurement of follicles with 2D US is often inaccurate and subject to significant intra- and interobserver variability In addition, a follicle is a three-dimensional (3D) structure and its volume is the most accurate measure of its size. Therefore, 3D transvaginal ultrasound in gynaecology and reproductive medicine has supposed a great advance, because it makes possible to obtain ovarian volumes during controlled ovarian stimulation

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other IVI Bilbao trials

Trials by the same sponsor.

NCT02992756 — Influence of PRGF (Plasma Rich in Growth Factors) Puncture in Ovaries With Low Follicular Reservetechniques · Phase 3 · terminated
NCT04758260 — Influence of the Antioxidant Treatment in the Oxidant-reduction Potential in Seminal Plasma in Men Whose Partners Will U · NA · withdrawn
NCT02996760 — Influence Instillation Plasma Rich in Growth Factors in Endometrial Cavity Endometrial Development in Assisted Reproduct · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05180019 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IVI Bilbao
Last refreshed: 2 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05180019.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing